Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional)
ID: 354117Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) program, aimed at fostering collaborative research in muscular dystrophy. This initiative seeks to support innovative studies, enhance resources for the research community, and train new researchers, with a focus on community engagement and patient-centered research. The program is critical for advancing understanding of muscular dystrophy and developing potential therapies, with up to $4.8 million available for three awards, each lasting up to five years. Applications are due by July 4, 2024, and interested parties can find more information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is announcing the opportunity for applications for the Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) program. This initiative seeks to foster collaborative research in muscular dystrophy while enhancing resources for the research community. The centers will support innovative studies and train new researchers, with an emphasis on community engagement and patient-centered research. Key funding details include up to $4.8 million available for three awards, each lasting up to five years, with applications due by July 4, 2024. Eligible applicants include educational institutions, nonprofits, for-profit organizations, and government entities. Research proposals must focus on various forms of muscular dystrophy, addressing mechanisms of disease and developing potential therapies. The MDSRC program underscores the importance of a coordinated national effort in advancing muscular dystrophy research, community engagement, and diversity in research participation. Applications must follow strict guidelines provided by the NIH to ensure compliance and maximize their potential for acceptance.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Morris K. Udall Discovery Centers without Walls (DCWoW) for Parkinson's Disease Research (RM1 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Morris K. Udall Discovery Centers without Walls (DCWoW) aimed at advancing research into Parkinson's Disease (PD). This initiative seeks to promote collaborative team science research to uncover the causes of PD, a chronic and progressive movement disorder affecting over half a million individuals in the U.S., along with their caregivers. The NOFO is expected to be released in autumn 2024, with applications due in early spring 2025, and will utilize the RM1 activity code. Interested applicants are encouraged to develop collaborative projects, as the estimated award date is set for December 1, 2025, with no cost-sharing or matching requirements.
    Polycystic Kidney Disease Core Centers (U54 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Polycystic Kidney Disease (PKD) Core Centers through a Notice of Funding Opportunity (NOFO) aimed at enhancing national research efforts in PKD. The initiative seeks to establish four Core Centers that will collaborate within the PKD Research Resource Consortium, focusing on developing and sharing essential research tools and resources while promoting scientific diversity and engagement among a wide range of investigators. Approximately $3.44 million in funding is anticipated for FY 2025, with applications due by November 15, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    NIH Medical Scientist Partnership Program (FM1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Medical Scientist Partnership Program (MSPP), a federal grant aimed at developing a diverse pool of predoctoral students pursuing combined doctoral degrees (e.g., M.D./Ph.D.) within the NIH Intramural Research Program. The program seeks to provide rigorous training in biomedical sciences, emphasizing research study design, critical thinking, and professional development, with participants receiving mentorship and networking opportunities to prepare them for leadership roles in biomedical careers. This initiative is crucial for enhancing the biomedical workforce by cultivating clinician-scientists equipped with essential skills, with applications due by August 8, 2025. Interested applicants can find more information and application guidelines at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies focused on musculoskeletal, rheumatic, and skin diseases, under the grant title PAR-24-036. This grant, which does not allow clinical trials, aims to support observational studies that collect critical data to inform future clinical research, particularly regarding disease symptoms, progression, and participant eligibility, while also exploring telehealth and digital outcomes. The initiative is designed to enhance the rigor of future clinical trials through comprehensive data collection from diverse populations, ultimately improving patient outcomes in affected communities. The grant provides up to $475,000 over four years, with applications opening on February 4, 2024, and funding decisions expected by late 2024. Interested applicants can find more information and guidelines at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Temporomandibular Disorder (TMD) Collaborative for Improving Patient-Centered Translational Research (TMD IMPACT)," aimed at establishing a national interdisciplinary research consortium to advance research and improve clinical care for Temporomandibular Disorders (TMDs). The initiative seeks to support rigorous basic and clinical research, enhance population health research, and train a diverse biomedical workforce through the establishment of TMD IMPACT Centers, which will include various cores and research projects. With an anticipated funding availability of $7 million annually for up to two awards, applications are due by January 11, 2025. Interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed)" aimed at enhancing resources for investigating undiagnosed diseases through a network of clinical sites. This initiative seeks to designate successful applicants as Diagnostic Centers of Excellence (DCoE), which will be responsible for generating clinical data to be shared with the Data Management Coordinating Center (DMCC), thereby promoting collaboration among clinicians and researchers to improve diagnostic capabilities, particularly for health disparity populations. The program does not provide direct budgetary support but allows successful applicants to apply for subawards for research activities, with applications open from April 15, 2023, until the final deadline of May 15, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the clinical validation of candidate biomarkers for neurological and neuromuscular disorders through the U44 Cooperative Agreement mechanism. This initiative aims to rigorously validate biomarkers that have already been identified and for which detection methods have been developed, ensuring compliance with FDA guidelines to establish their clinical sensitivity and specificity. This program is crucial for advancing therapeutic development in the field of brain health, with funding potentially reaching $700,000 for Phase I and $1.5 million for Phase II projects. Interested applicants must adhere to specific submission guidelines and deadlines, with the application closing on June 22, 2026. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-096.html.
    Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)." This initiative aims to promote the discovery and early evaluation of candidate biomarkers that can facilitate the clinical development of neurotherapeutics and their application in clinical practice, focusing on both animal studies and preliminary human evaluations. The funding is structured as a phased R61/R33 award, where the R61 phase emphasizes proof-of-concept studies using human samples, while the R33 phase focuses on clinical validation for specified uses. Interested applicants, including various educational and community organizations, must submit their proposals by May 7, 2025, and can find additional details and application guidelines at the provided NIH link. For inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.